Coronavirus (COVID19) Dashboard . .. 2023 [cited 2023 Dec, 28 : .
. .. 2023 [cited 2023 Jan, 12 : .
Global . .. net/covid19/global-covid-19-case-fatality-rates/., 22 : .
Pablos JL,Abasolo L,Alvaro-Gracia JM,Blanco FJ,Blanco R,Castrejón I .2020 .Prevalence of hospital PCRconfirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases. Ann Rheum Dis, 79 : 1170.
Santos CS,Morales CM,Álvarez ED,Castro CÁ,Robles AL,Sandoval TP .2020 .Determinants of COVID-19 disease severity in patients with underlying rheumatic disease. Clin Rheumatol, 39 : 2789-96.
Gianfrancesco M,Hyrich KL,Al-Adely S,Carmona L,Danila MI,Gossec L .2020 .Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis, 79 : 859-66.
Mikuls TR,Johnson SR,Fraenkel L,Arasaratnam RJ,Baden LR,Bermas BL .2021 .American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID19 Pandemic: Version 3. Arth Rheumatol, 73 : 1-12.
Caruso A,Caccuri F,Bugatti A,Zani A,Vanoni M,Bonfanti P .2021 .Methotrexate inhibits SARS-CoV-2 virus replication “in vitro. ” J Med Virol, 93 : 1780-5.
Schälter F,Dürholz K,Bucci L,Burmester G,Caporali R,Figuereido C .2021 .Does methotrexate influence COVID19 infection? Case series and mechanistic data. Arth Res Ther, 23 : 166-70.
Coronavirus Disease 2019,- Disease 2019 .2020 .. (COVID-19) | 2020 Interim Case Definition, Approved April 5, : .
Yousaf A,Gayam S,Feldman S,Zinn Z,Kolodney M. .2021 .Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study. J Am Acad Dermatol, 84 : 70-5.
Veenstra J,Buechler CR,Robinson G,Chapman S,Adelman M,Tisack A .2020 .Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak. J Am Acad Dermatol, 83 : 1696-703.
Opdam MAA,Benoy S,Verhoef LM,Van Bijnen S,Lamers-Karnebeek F,Traksel RAM .2022 .Identification of Risk Factors for COVID-19 Hospitalization in Patients with Anti-Rheumatic Drugs: Results from a Multicenter Nested Case Control Study. Clin Pharmacol Ther, 111 : 1061-5.
Topless RK,Green R,Morgan SL,Robinson PC,Merriman TR,Gaffo AL .2022 .Folic acid, and methotrexate use and their association with COVID-19 diagnosis and mortality: an analysis from the UK BIOBANK. , 12 : e062945.
Haberman RH,Castillo R,Chen A,Yan D,Ramirez D,Sekar V .2020 .-19 in Patients with Inflammatory Arthritis: A Prospective Study on the Effects of Comorbidities and Disease-Modifying Antirheumatic Drugs on Clinical Outcomes. Arth Rheumatol (Hoboken. , 72 : 1981-9.
Thomas DC,Chablani D,Parekh S,Pichammal RC,Shanmugasundaram K,Pitchumani PK .2022 .Dysgeusia: A review in the context of COVID-19. J Am Dent Assoc, 153 : 251-64.
Van Kessel S,Olde Hartman T,Lucassen P .2022 .Post-acute and long-COVID-19 symptoms in patients with mild diseases: a systematic review. Fam Pract, 39 : 159-67.
Strangfeld A,Schäfer M,Gianfrancesco MA,LawsonTovey S,Liew JW,Ljung L .2021 .Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis, 80 : 930-42.
Kihara M,Sugihara T,Asano J,Sato M,Kaneko H,Muraoka S .2022 .Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID19 Global Rheumatology Alliance physician-reported registry. Clin Rheumatol, 41 : 3661-73.
Alpizar-Rodriguez D,Irazoque-Palazuelos F,RodriguezReyne TS,Zamora E,Friedmann DXX,Ortiz AC .2021 .POS1242 Factors associated with mortality in patients with rheumatic diseases and COVID-19 in Mexico. Ann Rheum Dis, 80 : 904-904.
Florence A,Nassim AA,Jean-David A,Yannick A,Blanca AB,Zahir A .2021 .Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: Data from the French RMD COVID-19 cohort of 694 patients. Ann Rheum Dis, 80 : 527-38.
Esatoglu SN,Tascilar K,Babaoğlu H,Bes C,Yurttas B,Akar S .2021 .-19 Among Patients with Inflammatory Rheumatic Diseases. Front Immunol, 12 : 1226.
Kridin K,Schonmann Y,Tzur Bitan D,Damiani G,Peretz A,Weinstein O .2021 .COVID19)-Associated Hospitalization and Mortality in Patients with Psoriasis: A Population-Based Study. Am J Clin Dermatol, 22 : 709-18.
Gracia JMÁ,Sanchez-Piedra C,Manero J,Ruiz-Lucea ME,López-Vives L,Bohorquez C .2021 .Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD open, 7 : e001925.